Circulating IncRNA DRAIC as a potential serum biomarker for predicting lymphatic and vascular spread in pancreatic cancer
Journal of Medical Biochemistry · 2026 · 45 (5) · 1149-1155
DOI: 10.5937/jomb0-63713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Biochemistry, 2026. Verfasst von Ying Che und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital Affiliated to Capital Medical University, Department of Gastroenterology, Beijing, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pancreatic cancer is notorious for its aggressive behavior and poor prognosis, largely due to delayed diagnosis and early dissemination. Identifying reliable serum biomarkers could enhance early detection and risk stratification. Long non-coding RNAs (lncRNAs) have been recognised as regulators of tumour biology; however, the clinical and biochemical relevance of lncRNA DRAIC in pancreatic cancer remains unclear.
Methods
Serum samples were obtained from 100 patients diagnosed with pathologically confirmed pancreatic cancer and 100 ageand sex-matched controls. Quantitative real-time polymerase chain reaction (qPCR) was employed to quantify the circulating DRAIC expression levels. We analysed the associations between serum DRAIC levels and clinicopathological characteristics, including vascular involvement and lymph node metastasis. Receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic and predictive performance of DRAIC. Paired serum samples obtained before and after surgical resection were additionally analysed.
Results
Serum DRAIC expression was significantly elevated in patients with pancreatic cancer compared with controls. ROC analysis demonstrated robust diagnostic potential (AUC = 0.943). Elevated DRAIC levels were significantly associated with lymph node metastasis and vascular involvement. DRAIC showed strong predictive performance for lymph node metastasis (AUC = 0.906), whereas its predictive value for vascular involvement was moderate. Notably, serum DRAIC levels were significantly reduced following surgical resection.
Conclusion
Circulating lncRNA DRAIC is markedly dysregulated in pancreatic cancer and demonstrates potential utility as a serum-based biochemical biomarker, particularly for evaluating lymph node metastasis. These findings provide a basis for further mechanistic studies and validation in larger cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Anzhen Hospital Affiliated to Capital Medical University, Department of Gastroenterology, Beijing, China.
- Zhongshan Hospital, Fudan University, Department of Gastroenterology, Shanghai, China.
Zitieren
APA
Che, Y., Zhang, T., Li, J., Jiang, X., Li, C., & Li, W. (2026). Circulating IncRNA DRAIC as a potential serum biomarker for predicting lymphatic and vascular spread in pancreatic cancer. Journal of Medical Biochemistry, 45(5), 1149-1155. https://doi.org/10.5937/jomb0-63713
Vancouver
Che Y, Zhang T, Li J, Jiang X, Li C, Li W. Circulating IncRNA DRAIC as a potential serum biomarker for predicting lymphatic and vascular spread in pancreatic cancer. Journal of Medical Biochemistry. 2026;45(5):1149-1155. doi:10.5937/jomb0-63713
BibTeX
@article{Che2026,
author = {Che, Ying and Zhang, Ting and Li, Jing and Jiang, Xiao and Li, Chao and Li, Wei},
title = {Circulating IncRNA DRAIC as a potential serum biomarker for predicting lymphatic and vascular spread in pancreatic cancer},
journal = {Journal of Medical Biochemistry},
year = {2026},
volume = {45},
number = {5},
pages = {1149--1155},
doi = {10.5937/jomb0-63713}
}
EUVIMED